Many studies comparing patients who have converted to home haemodialysis have confirmed that, compared to 3-times-weekly in-centre haemodialysis, more frequent home haemodialysis may offer the following health and quality-of-life benefits:

  • Improved survival1
  • More energy2-5
  • Less stress on your heart6,7
  • Better blood pressure control with fewer medications8,9
  • Feel less depressed10
  • More likely to receive a kidney transplant11
  • Feel much better after treatment12
  • Fewer fluid and diet restrictions13,14
  • Sleep better15
  • Ability to keep working or go back to work16
  • More satisfaction with your sex life17
  • Taking control of your life

Despite the health benefits that more frequent home haemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. Home haemodialysis with the NxStage System One requires a patient and partner who are committed to being trained on and following the guidelines for proper system operation.

The reported benefits of home haemodialysis may not be experienced by all patients.

The NxStage System One is a prescription device and, like all medical devices, involves some risks. The risks associated with haemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in haemodialysis therapies may add additional risks including air entering the bloodstream, and blood loss due to clotting or accidental disconnection of the blood tubing set. Patients should consult with their doctor to understand the risks and responsibilities of home and/or more frequent haemodialysis using the NxStage System One.

Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.

Certain risks associated with haemodialysis treatment are increased when performing nocturnal therapy due to the length of treatment time and because therapy is performed while the patient and care partner are sleeping. These risks include, but are not limited to, blood access disconnects and blood loss during sleep, blood clotting due to slower blood flow or increased treatment time or both, and delayed response to alarms when waking from sleep. Patients should consult with their physician to understand the risks and responsibilities associated with home nocturnal haemodialysis using the NxStage System One.

References:

  1. Weinhandl ED, Lie J, Gilbertson DT, Arneson TJ, Collins AJ. Survival in daily home haemodialysis and matched thrice-weekly in-centre haemodialysis patients. J Am Soc Nephrol. 2012;23(5):895-904.
  2. Finkelstein FO, Schiller B, Daoui R, et al. At-home short daily haemodialysis improves the long-term health-related quality of life. Kidney Int. 2012;82(5): 561-569.
  3. Heidenheim PA, Muirhead N, Moist L, Lindsay RM. Patient quality of life on quotidian haemodialysis. Am J Kidney Dis. 2003;42(1)(suppl 1):S36-S41.
  4. Ting GO, Kjellstrand C, Freitas T, Carrie BJ, Zarghamee S. Long-term study of high-comorbidity ESRD patients converted from conventional to short daily haemodialysis. Am J Kidney Dis. 2003;42(5):1020-1035.
  5. Goldfarb-Rumyantzev AS, Leypoldt JK, Nelson N, Kutner NG, Cheung AK. A crossover study of short daily haemodialysis. Nephrol Dial Transplant. 2006;21:166-175.
  6. Kjellstrand CM, Ing T. Daily haemodialysis history and revival of a superior dialysis method. ASAIO J. 1998;44(3):117-122.
  7. Jefferies HJ, Virk B, Schiller B, Moran J, McIntyre CW. Frequent haemodialysis schedules are associated with reduced levels of dialysis-induced cardiac injury (myocardial stunning). Clin J Am Soc Nephrol. 2011;6(6):1326-1332.
  8. FHN Trial Group. In-centre haemodialysis six times per week versus three times per week. N Engl J Med. 2010;363(24):2287-2300.
  9. Jaber BL, Collins AJ, Finkelstein FO, et al. Daily haemodialysis (DHD) reduces the need for antihypertensive medications. Abstract presented at American Society of Nephrology Conference, October 29, 2009.
  10. Finkelstein FO, Wuerth D, Troidle LK, Finkelstein SH. Depression and end-stage renal disease: a therapeutic challenge. Kidney Int. 2008;74(7):843-845.
  11. Weinhandl E, Liu J, Gilbertson D, Arneson T, Collins A. Transplant incidence in frequent haemodialysis and matched thrice-weekly haemodialysis patients. Poster presented at National Kidney Foundation Spring Clinical Meeting, 2012.
  12. Jaber BL, Lee Y, Collins AJ, et al. Effect of daily haemodialysis on depressive symptoms and postdialysis recovery time: interim report from the FREEDOM (Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements) Study. Am J Kidney Dis. 2010;56(3):531-539.
  13. Spanner E, Suri R, Heidenheim AP, Lindsay RM. The impact of quotidian haemodialysis on nutrition. Am J Kidney Dis. 2003;42(1 suppl):30-35.
  14. Galland R, Traeger J, Arkouche W, Cleaud C, Delawari E, Fouque D. Short daily haemodialysis rapidly improves nutritional status in haemodialysis patients. Kidney Int. 2001;60(4):1555-1560.
  15. Jaber BL, Schiller B, Burkart JM, et al. Impact of short daily haemodialysis on restless legs symptoms and sleep disturbances. Clin J Am Soc Nephrol. 2011;6(5):1049-1056.
  16. Kraus MA, Cox CG, Summitt CL, et al. Work and travel in a large Short Daily Haemodialysis (SDHD) program. Abstract presented at American Society of Nephrology Annual Conference, 2007.
  17. Kraus M, Finkelstein FO, Daoui R, et al. Short Daily Haemodialysis (SDHD) improves overall Quality of Life (QOL) and physical intimacy: interim results from the FREEDOM study. Abstract presented at the American Society of Nephrology Conference, 2011.

APM1601 Rev. A